Matsubara et al. [17] established an animal myocardial ischemia–reperfusion model and showed that the infusion of GLP-1 and human transferrin could significantly prolong the half-life of the drug and improve the wall motion score index and the left ventricular ejection fraction, confirming that GLP-1 intervention could significantly reduce the infarct size, improve the wall motion index and left ventricular ejection fraction after reperfusion, and ameliorate myocardial reperfusion injury. Here, GLP1R is linked to myocardial ischemia.